Sperm DNA fragmentation and mitochondrial potential predict IVF outcomes in asthenozoospermia
This retrospective cohort study, conducted from January 2023 to June 2024, evaluated 320 asthenozoospermic men and 100 controls with normal semen parameters undergoing IVF-embryo transfer. The study assessed sperm DNA fragmentation index (DFI), reactive oxygen species (ROS), and mitochondrial membrane potential (MMP) as exposures.
Asthenozoospermic patients showed significantly higher DFI and ROS and lower MMP compared to controls. In multivariate analysis, DFI and MMP were independent predictors of clinical pregnancy rate. The low DFI/high MMP group achieved significantly higher fertilization, pregnancy, and live birth rates than the high DFI/low MMP group. The combination of DFI and MMP had an AUC of 0.771 for predicting clinical pregnancy, greater than DFI alone (AUC = 0.643) or MMP alone (AUC = 0.651).
Safety and tolerability were not reported. Key limitations include the retrospective design and lack of reporting on whether the study was randomized or controlled for confounders beyond multivariate adjustment. The practice relevance suggests DFI and MMP assessment may guide patient management in assisted reproductive technologies for asthenozoospermic patients, but findings are associative only.